Artiva Biotherapeutics, Inc. (ARTV)

11.09 -7.12% (-0.85)

Over 5Y: -7.6%

2026-08-28
5 10 15
2024 2025 2026

Financials Quarterly

Q1 '23 — Revenue: 989K Q1 '23 — Net Income: -16.7M Q2 '23 — Revenue: 3.5M Q2 '23 — Net Income: -11.3M Q3 '23 — Revenue: 26.7M Q3 '23 — Operating Cash Flow: -10.7M Q3 '23 — Free Cash Flow: -10.9M Q3 '23 — Net Income: 11.3M Q4 '23 — Revenue: 1.8M Q4 '23 — Operating Cash Flow: -10.7M Q4 '23 — Free Cash Flow: -11.3M Q4 '23 — Net Income: -12M Q1 '24 — Revenue: 251K Q1 '24 — Operating Cash Flow: -15.1M Q1 '24 — Free Cash Flow: -15.1M Q1 '24 — Net Income: -14M Q2 '24 — Revenue: 0 Q2 '24 — Operating Cash Flow: -13.7M Q2 '24 — Free Cash Flow: -14.1M Q2 '24 — Net Income: -17.8M Q3 '24 — Revenue: 0 Q3 '24 — Operating Cash Flow: -11.6M Q3 '24 — Free Cash Flow: -11.7M Q3 '24 — Net Income: -17.5M Q4 '24 — Revenue: 0 Q4 '24 — Operating Cash Flow: -14.7M Q4 '24 — Free Cash Flow: -14.7M Q4 '24 — Net Income: -16.1M Q1 '25 — Operating Cash Flow: -19.8M Q1 '25 — Free Cash Flow: -20.4M Q1 '25 — Net Income: -20.3M Q2 '25 — Operating Cash Flow: -23M Q2 '25 — Free Cash Flow: -24M Q2 '25 — Net Income: -21.3M Q3 '25 — Operating Cash Flow: -19.2M Q3 '25 — Free Cash Flow: -19.8M Q3 '25 — Net Income: -21.5M Q4 '25 — Operating Cash Flow: -14.7M Q4 '25 — Free Cash Flow: -15.1M Q4 '25 — Net Income: -20.8M Q1 '26 — Operating Cash Flow: -20.9M Q1 '26 — Free Cash Flow: -21.2M Q1 '26 — Net Income: -23.5M Q2 '26 — Operating Cash Flow: -20.4M Q2 '26 — Free Cash Flow: -20.8M Q2 '26 — Net Income: -25M -15M 0 15M 30M
Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
Accruals -4.2%
ROA -24.6%
ROCE -27.2%
ROE -26.1%
Asset turnover —
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROIC —
SBC / sales —

0 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

8.2
Current ratio 24.2×
ND/EBITDA —
Cash runway 4.5 yr
Cash / Debt 31763.1×
Debt / Eq 3.2e-05×
Debt payback 0.0 yr
Quick ratio 24.2×
F-score 1.3 pts
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales/sh Y/Y -100.0%
Sales Q/Q -100.0%
Shares change +117.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.